24/7 Market News Snapshot 15 October, 2024 – Hoth Therapeutics, Inc. Common Stock (NASDAQ:HOTH)

October 15, 2024

DENVER, Colo., 15 October, 2024 (247marketnews.com) – (NASDAQ:HOTH) are discussed in this article.
Hoth Therapeutics, Inc. (NASDAQ:HOTH) is experiencing notable excitement in the investment community as shares surge in pre-market trading, currently reaching $0.994—a remarkable increase of 21.22% from the previous close of $0.820. This upward movement is complemented by a substantial trading volume of 2.59 million shares, indicating a heightened investor interest and optimism surrounding the company’s initiatives. Continuous market observation hints at a potential breakout, suggesting further gains could be on the horizon.

Simultaneously, Hoth Therapeutics has achieved a significant milestone by securing a U.S. patent for its innovative treatment for Alzheimer’s disease, HT-ALZ. This accomplishment not only strengthens the company’s intellectual property portfolio but also propels the clinical development of this promising therapy. HT-ALZ targets the Substance P/Neurokinin-1 Receptor pathway, an essential mechanism associated with neuroinflammation, which has been increasingly acknowledged for its contribution to the progression of Alzheimer’s disease. Encouraging preclinical findings have indicated that HT-ALZ may effectively mitigate neuroinflammation and enhance cognitive functions such as memory and learning.

With the patent secured, Hoth is strategically positioning itself to lead in the Alzheimer’s treatment domain, gearing up to advance HT-ALZ into human clinical trials with a focus on assessing its safety and efficacy in alleviating cognitive decline linked to Alzheimer’s. Robb Knie, CEO of Hoth Therapeutics, emphasized the significance of this patent, stating that it marks a critical transition for the company, transforming HT-ALZ from research to clinical phases. The commitment to expedite research in neuroinflammation modulation reveals Hoth’s dedication to discovering impactful therapies that could greatly enhance the lives of those affected by Alzheimer’s disease.

Overall, Hoth Therapeutics remains a dynamic player in the biopharmaceutical landscape, dedicated to pioneering effective treatments aimed at improving patient outcomes through innovative scientific solutions.

Related news for (HOTH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.